Nanoparticle Based Screening Is Fastest Growing Segment Fueling The Growth Of Lung Cancer Diagnostic And Screening Market

Global Lung Cancer Diagnostic And Screening Market Size
 Global Lung Cancer Diagnostic And Screening Market Size


 
Lung cancer diagnostic and screening products help to detect the presence of cancer in the lungs at an early stage. These include imaging tests that can detect lung abnormalities and biopsy procedures to analyze lung tissue samples. Early detection improves treatment effectiveness and survival rates of lung cancer patients.

 

The global Lung Cancer Diagnostic And Screening Market is estimated to be valued at US$ 2458.7 Mn in 2023 and is expected to exhibit a CAGR of 10.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.



Market key trends:
Rising adoption of nanoparticles-based screening is driving the growth of the lung cancer diagnostic and screening market. Nanoparticles are being widely used to develop new approaches for lung cancer screening and diagnostics. For instance, gold nanoparticles are being utilized to develop tests to detect tumor-specific proteins and tumor DNA in blood or sputum samples. They enhance the sensitivity and specificity of screening and diagnostic tests. Researchers are also exploring the use of nanoparticles as carriers for targeted drug delivery to lung cancer sites post-detection. This reduces toxicity and enhances therapeutic efficacy.
Segment Analysis

The global lung cancer diagnostic and screening market is segmented on the basis of type, product, end user and region. Based on type, the market is segmented into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The non-small cell lung cancer (NSCLC) segment dominates the market due to its higher prevalence rate. NSCLC accounts for around 85% of all lung cancer cases.

Key Takeaways

Market size

The Global Lung Cancer Diagnostic And Screening Market Size is expected to witness high growth, exhibiting CAGR of 10.1%  over the forecast period, due to increasing prevalence of lung cancer worldwide. According to GLOBOCAN estimates, lung cancer burden has risen to 2.21 million new cases in 2020 from 1.80 million new cases in 2018.

Regional analysis

Regionally, North America dominates the lung cancer diagnostic and screening market and is expected to continue its dominance over the forecast period. This is attributed to increasing funding from public and private bodies for lung cancer research, rising awareness regarding early diagnosis and screening, and significant per capita healthcare spending in the region.

Key players

Key players operating in the lung cancer diagnostic and screening market are Abbott, Illumina, Inc., Thermo Fischer Scientific, QIAGEN, Quest Diagnostics Incorporated, NeoGenomics, NanoString, Myriad Genetics Inc. , F. Hoffmann-La Roche Ltd, Danaher, Agilent Technologies, Inc., AstraZeneca, Sanofi, and Janssen Pharmaceuticals, Inc. These players are focusing on developing innovative diagnostic and screening technologies to gain a competitive edge in the market.

 

Get More Insights On This Topic: https://www.pressreleasebulletin.com/lung-cancer-diagnostic-and-screening-market-size/

Post a Comment

Previous Post Next Post